Inotuzumab ozogamicin
Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody Inotuzumab (HY-P99264) conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin and G544 bind human CD22 with similar affinities (Kd ≈ 150 pM). Inotuzumab ozogamicin has demonstrated efficacy against CD22+ B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin can be used in the research of acute lymphoblastic leukemia.
For research use only. We do not sell to patients.
- CAS No.: 635715-01-4
-
Storage:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
HY-P3239
Belantamab mafodotin -
HY-P9985
Disitamab vedotin -
HY-141601
Telisotuzumab vedotin -
HY-P99813
Patritumab deruxtecan -
HY-P99107A
Brentuximab vedotin (solution) -
HY-109539
Gemtuzumab ozogamicin -
HY-152963
Tisotumab vedotin -
HY-132253
Polatuzumab vedotin -
HY-P99349
Loncastuximab tesirine -
HY-P99681
Labetuzumab govitecan -
HY-P99683
Ladiratuzumab vedotin -
HY-141606
Anetumab ravtansine
Biological Activity
Description
IC50 & Target
Kd ≈ 150 pM (CD22)[1]
In Vitro
Inotuzumab ozogamicin exerts highly potent cytotoxic activity against a vari-
ety of CD22-positive B-cell origin cancer cell lines[1].
Inotuzumab ozogamicin and G544
bind human CD22 with similar affinities (KD ≈ 150 pM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Format
-
Human IgG4 kappa
Chemical Information
-
CAS No. 635715-01-4
-
Appearance Solid
-
Color White to off-white
-
SMILES
[Inotuzumab ozogamicin]
-
Synonyms
CMC-544; PF-5208773; WAY-207294
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
-80°C, protect from light
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Shor B, et al. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol. 2015;67(2 Pt A):107-116. [Content Brief]
[2]. Kantarjian H, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403-411. [Content Brief]
[3]. Advani A, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085-2093. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Inotuzumab ozogamicin Related Classifications
HY-P9959 Related Classifications
Powered by Bioz
Keywords
- Inotuzumab ozogamicin
- 635715-01-4
- CMC-544
- PF-5208773
- WAY-207294
- CMC544
- CMC 544
- PF5208773
- PF 5208773
- PF-5208773
- WAY207294
- WAY 207294
- WAY-207294
- Antibody-Drug Conjugates (ADCs)
- CD22
- B-cell malignancy models
- diffuse large B-cell lymphoma
- non-Hodgkin’s lymphoma
- apoptosis
- calicheamicin
- DNA double-strand breaks
- B-cell
- follicular lymphoma
- acute lymphocytic leukemia
- Inhibitor
- inhibitor
- inhibit